Skip to content

Monopar Therapeutics MNPR Investing Cash Flow

Investing Cash Flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$131M+73.7%
Eli Lilly logo
Eli LillyLLY
-$3.92B-16.8%
Bausch Health Companies logo
Bausch Health CompaniesBHC
-$139M-6.9%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$49M-141%
Prime Medicine logo
Prime MedicinePRME
$43.39M+191%
Wave Life Sciences logo
Wave Life SciencesWVE
-$438K-165%

Other financials

Income statement

See full
Revenue-
Operating income-$5.2M-62.2%
Net income-$3.9M-48.3%
EPS (diluted)-$0.19

Balance sheet

See full
Cash & equivalents$52.5M+32.3%
Total debt$230.4K+2,692%
Total equity$135.4M+153%
Total assets$138.0M+150%

Cash flow

See full
Operating cash flow-$3.5M+38.7%

Valuation

See full
Market cap$587.04M+192%
Enterprise value$534.72M+232%

Returns & leverage

See full
Return on equity-15.9%-6.6pp
Debt / equity0.0×
Current ratio56×

Where this comes from

Reported directly by Monopar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monopar Therapeutics's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Monopar Therapeutics's investing cash flow?
Monopar Therapeutics (MNPR) reported investing cash flow of -$5.58M in Q1 2026.
How has Monopar Therapeutics's investing cash flow changed year-over-year?
Monopar Therapeutics's investing cash flow decreased by 1613.7% year-over-year, from -$325.83K to -$5.58M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.